Preoperative Anemia in the Oncology Population and Associated Mortality

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Chile

About this trial

Anemia is a highly prevalent condition in the surgical population (1, 2). On the other hand, the oncology population is at higher risk of developing anemia due to specific treatments for the disease, such as chemotherapy and radiotherapy. Preoperative anemia has been associated with an increased risk of postoperative morbidity and even mortality (3). Despite this, the prevalence of preoperative anemia in the Chilean oncology population has not been quantified. To answer this question, a retrospective cohort study was designed between January and December 2022 to quantify the prevalence of anemia in the surgical population of the National Cancer Institute. In addition, the impact on morbidity and mortality at 30 days, 6 months, and 1 year will be evaluated. Statistical analysis will be performed using R. Studio Version 2023.09.1+494 (2023.09.1+494).

Eligibility criteria

Qualifiers

Patients over 18 years of age

Oncologic surgery with curative intent

Disqualifiers

Emergency surgery

Patients who received a preoperative transfusion

Patients without a preoperative blood count

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

850 Participants
are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators